• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Venous thromboembolism after vaginal delivery rising, preventative measures lacking

byDenise PongandLeah Hawkins Bressler, MD, MPH
September 21, 2014
in Cardiology, Emergency, Obstetrics
Reading Time: 3 mins read
Venous thromboembolism after vaginal delivery rising, preventative measures lacking
Share on FacebookShare on Twitter

1. Current rates of venous thromboembolism (VTE) prophylaxis during vaginal delivery hospitalizations are low, with patients having a history of VTE and/or hypercoagulability most likely to receive it.

2. Other risk factors for VTE such as obesity and smoking were not as strongly associated with VTE prophylaxis.

Evidence Rating Level: 2 (Good)

Study Rundown: Venous thromboembolism (VTE) is a common cause of pregnancy-related morbidity and mortality, and rates of VTE events have been increasing in the United States. VTE includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE is more common after cesarean delivery, and prevention of VTE in the U.S. has centered around cesarean deliveries. However, the majority of women undergo vaginal deliveries, and a greater proportion of VTE events occur among women delivering vaginally. Current guidelines for women undergoing vaginal deliveries recommend prophylaxis only for those women who are hypercoagulable and/or have had a prior thromboembolic event. VTE rates have been increasing over time. Some attribute this rise partially to increasing rates of medical risk factors including obesity, smoking and other chronic diseases, and prior work has produced some evidence to support this hypothesis. In the present study, authors found that current VTE prophylaxis practices are consistent with existing guidelines as described above; other known risk factors for VTE such as obesity are not strongly associated with use of prophylaxis. These findings suggest that there may be room to decrease the incidence of VTE by employing prophylaxis for women with multiple risk factors.

Limitations include retrospective design and use of claims data. Future studies exploring cost-effectiveness of VTE prophylaxis among patients with other risk factors are needed to determine whether and how national guidelines should be modified to decrease the incidence of VTE.

Click to read the study in AJOG

RELATED REPORTS

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis

Relevant Reading: Thromboembolism in pregnancy: recurrence risks, prevention and management

In-Depth [retrospective cohort]: This study evaluated the incidence of VTE, defined as deep vein thrombosis (DVT) or pulmonary embolism (PE), and the use of mechanical or pharmacologic VTE prophylaxis among 2,673,986 women who were hospitalized for a vaginal delivery. Outcomes of interest were DVT, PE, and VTE events, as noted by ICD-9 codes on patient records.

Rates of VTE have increased between 2006 and 2012. Only 2.6% of women in the study received VTE prophylaxis; 67.5% of these women received mechanical prophylaxis in the form of graduated compression stockings or pneumatic compression devices. Patients with a history of VTE and hypercoagulability were more likely to receive prophylaxis (RR 10.14, CI 9.74-10.56 and RR 9.32, CI 8.96-9.71 respectively). Prophylaxis was more likely to occur in patients with other established risk factors for VTE, such as obesity (RR 1.29, CI 1.25-1.34).

More from this author: Unexpected delivery outcomes associated with postpartum depression, Postoperative pain similar in robotic and conventional laparoscopy for gynecologic procedures, Intrahepatic cholestasis of pregnancy linked to poor outcomes, Severe acne linked to endometriosis, Postpartum pelvic floor muscles may have limited value

Image: GNUFree/Wiki

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: vaginal deliveryvenous thromboembolism
Previous Post

Vitamin supplementation does not reduce the risk of cataract formation

Next Post

Gemcitabine, chokeberries synergistic in pancreatic cancer model

RelatedReports

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Cardiology

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

April 9, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Hematology

Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis

May 20, 2025
#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients
StudyGraphics

#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients

March 10, 2025
Next Post
Adjuvant gemcitabine improves long-term survival rates of patients with pancreatic cancer

Gemcitabine, chokeberries synergistic in pancreatic cancer model

A quarter of youths with assault injury own a gun

U.S. firearm fatality rates differ by state, race, and ethnicity

Early weight gain linked to obesity and cardiovascular health

2 Minute Medicine Rewind September 14 – September 21, 2014

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Nirsevimab (Beyfortus) may reduce severe respiratory syncytial virus infections among infants
  • An artificial intelligence (AI) tool achieved high diagnostic accuracy for the identification and prediction of sepsis
  • Use of long-acting broadly neutralizing antibodies may delay human immunodeficiency virus (HIV) rebound following discontinuation of antiretroviral therapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.